Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aadi Bioscience, Inc. (AADI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
13.95+0.70 (+5.28%)
At close: 04:00PM EDT
13.95 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close13.25
Open13.44
Bid13.95 x 800
Ask14.52 x 800
Day's Range13.40 - 14.05
52 Week Range11.00 - 32.50
Volume102,699
Avg. Volume131,468
Market Cap293.184M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-8.81
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AADI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aadi Bioscience, Inc.
    Analyst Report: Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
    Rating
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
  • PR Newswire

    Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing

    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock ("Common Stock") at a price of $12.50 per share, reflecting the closing price on September 21, 2022 on NASDAQ, an

  • PR Newswire

    Aadi Bioscience Announces Participation in Upcoming September Investor Conferences

    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the Company will be participating in and hosting one-on-one meetings at the following conferences during September:

  • PR Newswire

    Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update

    Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2022.

Advertisement
Advertisement